Inicio600812 • SHA
add
North China Pharmaceutical Co Ltd
Cierre anterior
6,23 ¥
Intervalo diario
6,21 ¥ - 6,36 ¥
Intervalo anual
4,03 ¥ - 6,91 ¥
Volumen medio
35,44 M
Relación precio-beneficio
134,32
Rentabilidad por dividendo
0,16 %
Bolsa de valores principal
SHA
Noticias sobre los mercados
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
(CNY) | sept 2024info | Cambio interanual |
---|---|---|
Ingresos | 2329,12 M | -15,04 % |
Gastos operativos | 539,22 M | -19,20 % |
Ingresos netos | 30,48 M | 2.035,14 % |
Margen de beneficio neto | 1,31 | 2.520,00 % |
Beneficios por acción | — | — |
EBITDA | 362,65 M | 6,65 % |
Tipo impositivo efectivo | 32,92 % | — |
Balance general
Activos totales
Responsabilidades totales
(CNY) | sept 2024info | Cambio interanual |
---|---|---|
Efectivo y a corto plazo | 1721,57 M | 15,99 % |
Activos totales | 21,71 mil M | 0,92 % |
Responsabilidades totales | 15,10 mil M | -0,95 % |
Patrimonio total | 6605,58 M | — |
Acciones en circulación | 1715,73 M | — |
Precio-valor contable | 1,99 | — |
Rentabilidad económica | 2,06 % | — |
Retorno sobre capital | 2,47 % | — |
Flujo de caja
Variación neta del flujo de caja
(CNY) | sept 2024info | Cambio interanual |
---|---|---|
Ingresos netos | 30,48 M | 2.035,14 % |
Efectivo de operaciones | 175,21 M | -46,70 % |
Efectivo de inversión | -153,19 M | 10,80 % |
Efectivo de financiación | -76,80 M | 67,74 % |
Variación neta del flujo de caja | -55,38 M | 30,27 % |
Flujo de caja libre | -660,87 M | -459,21 % |
Información sobre la empresa
North China Pharmaceutical Group Corp., is a pharmaceutical manufacturer in China. NCPC was one of the key construction projects during China's First Five-Year Plan. After five years of construction since the foundation date in June 1953, the first successful pharmaceutical production, started in June 1958. Being one of the antibiotic producers both in technology and production scale at that time, NCPC created a history of commercial production of antibiotics in China. It has 45 years of development experience. NCPC has been taking the lead in the Chinese pharmaceutical industry in key economic indexes, ranked as one of the Top500 Enterprises and the best profit-makers in China. By the end of 2002, the total assets of the company were valued at US$2 billion, with 18,500 employees. In 2002, NCPC claimed a domestic sales revenue of US$700 million and export sales of US$100 million. Wikipedia
Fundación
20 dic 1992
Empleados
10.159